These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer. Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985 [TBL] [Abstract][Full Text] [Related]
51. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer]. Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804 [TBL] [Abstract][Full Text] [Related]
52. Role of 2-[18F]fluoro-2-deoxyglucose positron emission tomography in preoperative management of solid-type small-sized lung cancer. Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M Ann Nucl Med; 2013 Jul; 27(6):515-22. PubMed ID: 23504519 [TBL] [Abstract][Full Text] [Related]
53. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. Lowe VJ; Hoffman JM; DeLong DM; Patz EF; Coleman RE J Nucl Med; 1994 Nov; 35(11):1771-6. PubMed ID: 7965154 [TBL] [Abstract][Full Text] [Related]
54. FDG PET: advantages for staging the mediastinum? Franzius C Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784 [TBL] [Abstract][Full Text] [Related]
55. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Kut V; Spies W; Spies S; Gooding W; Argiris A Am J Clin Oncol; 2007 Feb; 30(1):45-50. PubMed ID: 17278894 [TBL] [Abstract][Full Text] [Related]
56. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
57. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Sundaresan SR; Patterson GA; Cooper JD AJR Am J Roentgenol; 1997 Feb; 168(2):417-24. PubMed ID: 9016218 [TBL] [Abstract][Full Text] [Related]
58. Detecting recurrent or residual lung cancer with FDG-PET. Inoue T; Kim EE; Komaki R; Wong FC; Bassa P; Wong WH; Yang DJ; Endo K; Podoloff DA J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649 [TBL] [Abstract][Full Text] [Related]
59. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. Hetzel M; Arslandemir C; König HH; Buck AK; Nüssle K; Glatting G; Gabelmann A; Hetzel J; Hombach V; Schirrmeister H J Bone Miner Res; 2003 Dec; 18(12):2206-14. PubMed ID: 14672356 [TBL] [Abstract][Full Text] [Related]
60. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]